Analysts Set Annexon, Inc. (NASDAQ:ANNX) PT at $14.43

Annexon, Inc. (NASDAQ:ANNX) has been assigned a consensus rating of “Buy” from the six ratings firms that are currently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have covered the stock in the last year is $14.43.

ANNX has been the topic of a number of recent research reports. Wells Fargo & Company upped their price objective on Annexon from $11.00 to $12.00 and gave the company an “overweight” rating in a research report on Wednesday, March 27th. JPMorgan Chase & Co. upped their price objective on Annexon from $11.00 to $13.00 and gave the company an “overweight” rating in a research report on Monday, April 1st. Bank of America upped their price objective on Annexon from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, March 28th. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Annexon in a research report on Wednesday, March 27th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a research report on Wednesday.

Insider Activity

In other news, CEO Douglas Love sold 5,782 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $5.54, for a total transaction of $32,032.28. Following the transaction, the chief executive officer now owns 196,121 shares of the company’s stock, valued at $1,086,510.34. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Over the last 90 days, insiders have sold 8,940 shares of company stock valued at $49,514. 19.11% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ANNX. SG Americas Securities LLC bought a new position in shares of Annexon during the third quarter valued at approximately $52,000. Tower Research Capital LLC TRC grew its stake in Annexon by 53.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 11,924 shares of the company’s stock worth $54,000 after purchasing an additional 4,141 shares in the last quarter. Forefront Analytics LLC grew its stake in Annexon by 18.3% in the third quarter. Forefront Analytics LLC now owns 31,680 shares of the company’s stock worth $75,000 after purchasing an additional 4,890 shares in the last quarter. Virtu Financial LLC bought a new position in Annexon in the fourth quarter worth approximately $221,000. Finally, Lighthouse Investment Partners LLC bought a new position in Annexon in the fourth quarter worth approximately $306,000.

Annexon Trading Up 2.4 %

NASDAQ:ANNX opened at $4.70 on Monday. The company has a market capitalization of $423.14 million, a P/E ratio of -2.64 and a beta of 1.14. Annexon has a 12 month low of $1.57 and a 12 month high of $8.40. The business’s 50-day moving average is $5.67 and its 200 day moving average is $4.15.

Annexon (NASDAQ:ANNX) last posted its earnings results on Tuesday, March 26th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.09. On average, research analysts forecast that Annexon will post -1.36 earnings per share for the current year.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.